Ranbaxy ramps up in biosimilars, but must compete in India first
This article was originally published in Scrip
Ranbaxy Laboratories plans to pursue biosimilars "vigorously". Its CEO and managing director, Arun Sawhney, said recently in New York that the company expects to launch at least three biosimilar drugs in India by 2015, including an anticancer next year. Reportedly, the anticancer product could potentially rake in annual sales 'in the hundreds of millions of dollars'.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.